首頁 > 市場調查報告書 > 製藥

糖尿病

市場調查報告書

商品編碼

2032630

速效胰島素市場報告：按產品、適應症、分銷管道和地區分類（2026-2034 年）

Rapid Acting Insulin Market Report by Product, Indication, Distribution Channel, and Region 2026-2034

出版日期: 2026年04月01日 | 出版商:

IMARC | 英文 148 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

2025年，全球速效胰島素市場規模達83億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到117億美元，2026年至2034年的複合年成長率為3.74%。推動市場成長的主要因素包括患者病情加重和死亡風險增加、公眾對個人化醫療日益成長的興趣以及研發投入的增加。

速效胰島素是一種用於治療糖尿病的胰島素，特別適用於控制餐後血糖值高峰。它的設計旨在模擬人體餐後自然產生的胰島素反應，注射後15分鐘內即可發揮作用。這種快速作用有助於透過調節葡萄糖代謝來有效控制血糖值。速效胰島素在注射後約1-2小時達到高峰效應，在此關鍵時間內有效降低高血糖值。這使得糖尿病患者能夠根據用餐時間調整注射時間，從而實現更個人化的治療方案。此外，它還能改善糖尿病管理，提高患者的生活品質，並降低血糖值控制不佳相關併發症的風險。

速效胰島素市場的趨勢與促進因素：

糖尿病在一般人群中的盛行率正在上升。

全球糖尿病發生率正以驚人的速度成長。久坐不動的生活方式、不健康的飲食習慣和肥胖是導致糖尿病盛行率上升的主要因素。隨著越來越多的人被診斷出患有糖尿病，對高效速效胰島素的需求也持續成長。速效胰島素在控制餐後血糖值的快速升高方面發揮著至關重要的作用，為患者提供了更快、更有效的血糖值控制方法。醫療專業人員正在增加速效胰島素的處方量，以滿足餐後即時的胰島素需求，並降低高血糖及其相關併發症的風險。隨著糖尿病患者人數的增加，藥廠正在加大對研發的投入，以改善速效胰島素的配方，提高其療效和患者的便利性。

持續的技術進步

醫療技術的創新徹底改變了胰島素輸注系統，使其更容易使用且更精準。胰島素筆、胰島素幫浦和持續血糖監測（CGM）設備在糖尿病患者中越來越受歡迎，使胰島素給藥更加便捷，劑量也更加精確。速效胰島素製劑的設計旨在與這些現代輸注系統完美配合，進一步提升了其市場需求。胰島素筆方便隱密地進行注射，而胰島素幫浦則可根據個體需求提供持續的個人化胰島素輸注。這些創新顯著改善了血糖控制，降低了低血糖風險，並全面提升了患者的生活品質。因此，速效胰島素與這些先進設備的兼容性是推動市場成長的關鍵因素。

提高對醫療保健基礎設施的認知和發展

人們對糖尿病及其管理的認知不斷提高，加之醫療基礎設施的不斷完善，顯著推動了速效胰島素的需求成長。糖尿病宣傳宣傳活動、教育推廣和篩檢計畫有助於患者早期診斷和及時干預，從而增加了尋求適當治療的人數。醫生和醫療專業人員正在增加速效胰島素的處方量，以幫助患者更好地控制餐後血糖，並預防高血糖發作和長期併發症。此外，各國政府和醫療機構也增加對糖尿病管理計畫的併發症，以改善包括速效胰島素在內的基本藥物的可近性。糖尿病意識的提高、醫療設施的改善以及治療成本效益的提升，共同為速效胰島素市場的擴張創造了有利環境。

The global rapid acting insulin market size reached USD 8.3 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 11.7 Billion by 2034, exhibiting a growth rate (CAGR) of 3.74% during 2026-2034. The increasing risks of severity and mortality among patients, the growing focus on personalized medicine among the masses, and the increasing investments in research and development (R&D) activities are some of the major factors propelling the market.

A rapid-acting insulin is a type of insulin used in the treatment of diabetes, specifically for managing post-meal blood sugar spikes. It is designed to mimic the body's natural insulin response after eating, with an onset of action within 15 minutes of injection. This swift action helps to control blood sugar levels effectively, as it works to regulate the body's metabolism of glucose. Rapid-acting insulin peaks in its effect around one to two hours after administration, enabling it to efficiently lower high blood sugar levels during this critical period. It allows individuals with diabetes to time their injections in correlation with meal consumption, providing a more personalized treatment approach. It enhances diabetes management, providing patients with a better quality of life and reducing the risk of complications associated with uncontrolled blood sugar levels.

Rapid Acting Insulin Market Trends/Drivers:

The Increasing Prevalence of Diabetes Among the Masses

The incidences of diabetes have been escalating at an alarming rate worldwide. Sedentary lifestyles, unhealthy dietary habits, and obesity are some of the key factors contributing to the rising incidence of diabetes. As more individuals are diagnosed with diabetes, the demand for effective and rapid-acting insulin continues to grow. Rapid-acting insulin plays a crucial role in managing post-meal blood sugar spikes, providing patients with a faster and more efficient way to control their glucose levels. Healthcare providers increasingly prescribe rapid-acting insulin to address the immediate insulin needs after meals, reducing the risk of hyperglycemia and associated complications. As the diabetic population expands, pharmaceutical companies are investing more in research and development to improve rapid-acting insulin formulations, enhancing their efficacy and convenience for patients.

Continual Technological Advancements

Innovations in medical technology have revolutionized insulin delivery systems, making them more user-friendly and accurate. Insulin pens, insulin pumps, and continuous glucose monitoring (CGM) devices have become increasingly popular among diabetes patients, facilitating easier administration and precise dosing of insulin. Rapid-acting insulin formulations are designed to work optimally with these modern delivery systems, further fueling their demand. Insulin pens offer discreet and convenient insulin delivery, while insulin pumps provide a continuous and personalized insulin infusion based on individual needs. These technological innovations have improved glycemic control, reduced the risk of hypoglycemic episodes, and enhanced patient's overall quality of life. As a result, the compatibility of rapid-acting insulin with these advanced devices has become a significant driving force behind the market's growth.

Increasing Awareness and Healthcare Infrastructure

Growing awareness about diabetes and its management, coupled with the expansion of healthcare infrastructure, has significantly contributed to the demand for rapid-acting insulin. Diabetes awareness campaigns, educational initiatives, and screening programs have led to early diagnosis and timely intervention for patients, increasing the number of individuals seeking appropriate treatment. Physicians and healthcare professionals are increasingly prescribing rapid-acting insulin to help patients achieve better post-prandial glucose control, preventing hyperglycemic episodes and long-term complications. Moreover, governments and healthcare organizations are investing in diabetes management programs, improving access to essential medications, including rapid-acting insulin. The combination of heightened awareness, better healthcare facilities, and increased affordability of diabetes treatment has created a favorable environment for the rapid-acting insulin market's expansion.

Rapid Acting Insulin Industry Segmentation:

The publisher provides an analysis of the key trends in each segment of the global rapid acting insulin market report, along with forecasts at the global, regional and country levels from 2026-2034. Our report has categorized the market based on product, indication and distribution channel.

Breakup by Product:

Lispro Insulin
Aspart Insulin
Glulisine Insulin

Lispro insulin dominates the market

Lispro insulin's popularity can be attributed to its fast onset of action, typically within a few minutes after administration, which helps control post-meal blood sugar spikes more effectively. This rapid action allows individuals with diabetes to time their insulin injections closer to meal consumption, providing greater flexibility and convenience in managing their blood glucose levels. Moreover, Lispro insulin is compatible with various insulin delivery devices, such as insulin pens and insulin pumps, further enhancing its ease of use and patient compliance. Apart from this, numerous physicians and healthcare providers frequently prescribe Lispro insulin due to its proven efficacy and safety profile. It has demonstrated its effectiveness in managing both type 1 and type 2 diabetes, making it a versatile option for a wide range of patients.

Breakup by Indication:

Type 1 Diabetes
Type 2 Diabetes

Type 2 diabetes hold the largest share in the market

Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance and impaired glucose regulation, leading to elevated blood sugar levels. Rapid-acting insulin plays a crucial role in the management of type 2 diabetes, particularly in addressing post-meal hyperglycemia. After a meal, individuals often experience a rapid increase in blood sugar levels, which can contribute to various health complications if left uncontrolled. As awareness about diabetes and its management continues to rise, coupled with the efforts to improve access to healthcare and diabetes care, the demand for rapid-acting insulin is expected to remain significant, solidifying its prominent position in the market. The increasing prevalence of type 2 diabetes, driven by factors like sedentary lifestyles, obesity, and an aging population, has resulted in a growing patient pool seeking diabetes management solutions.

Breakup by Distribution Channel:

Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Stores

Drug stores and retail pharmacies hold the largest share in the market

Drug stores and retail pharmacies are widespread and easily accessible, making them convenient points of purchase for patients seeking their diabetes medications. This accessibility ensures that patients can promptly refill their prescriptions and access essential rapid-acting insulin whenever needed, promoting better adherence to treatment regimens and overall diabetes management. Moreover, drug stores and retail pharmacies offer a diverse range of rapid-acting insulin products, providing patients with multiple options to choose from based on their specific needs and preferences. Pharmacists at these locations also play a vital role in patient education, helping individuals understand proper insulin administration, potential side effects, and the importance of medication adherence. Additionally, drug stores and retail pharmacies often participate in health insurance plans, which further facilitates access to rapid-acting insulin for patients, potentially reducing the financial burden associated with diabetes management.

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

North America exhibits a clear dominance, accounting for the largest rapid acting insulin market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America boasts a high prevalence of diabetes, with both the United States and Canada experiencing an alarming increase in diabetes cases over the years. The region has a well-established healthcare infrastructure that emphasizes diabetes management and treatment. Access to advanced medical technologies, insulin delivery devices, and continuous glucose monitoring systems has enhanced patient care and contributed to the widespread adoption of rapid-acting insulin therapies. Moreover, North America is at the forefront of research and development in the pharmaceutical industry, leading to the introduction of innovative and effective rapid-acting insulin formulations. This continuous focus on advancements ensures that the region remains a key player in shaping the future of diabetes treatment. Furthermore, robust healthcare policies and insurance coverage in North America facilitate easier access to diabetes medications, including rapid-acting insulin, for a large portion of the population. This accessibility has significantly contributed to the region's dominant market share.

Competitive Landscape:

Pharmaceutical companies are investing heavily in R&D to discover and develop innovative rapid-acting insulin formulations. They aim to improve the pharmacokinetics, onset of action, and duration of these insulins to better meet the needs of patients. Additionally, companies are exploring new insulin delivery systems, such as ultra-rapid-acting insulins, oral insulin formulations, and inhalable insulin, to enhance convenience and patient compliance. Moreover, companies are pursuing regulatory approvals from health authorities in various countries to expand the market reach of their rapid-acting insulin products. Furthermore, leading players are focusing on expanding their presence in emerging economies with a high prevalence of diabetes. By increasing access to rapid-acting insulin in these regions, they can tap into untapped market potential and improve diabetes management globally. Additionally, pharmaceutical companies are actively involved in patient education and support programs to raise awareness about diabetes management and the importance of insulin therapy.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Adocia
Biocon Limited
Eli Lilly and Company
Gan & Lee Pharmaceuticals Co. Ltd.
Geropharm
MannKind Corporation
Merck & Co. Inc.
Novo Nordisk A/S
Sanofi S.A.
Wockhardt Ltd.

Key Questions Answered in This Report:

How has the global rapid acting insulin market performed so far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global rapid acting insulin market?
What is the impact of each driver, restraint, and opportunity on the global rapid acting insulin market?
What are the key regional markets?
Which countries represent the most attractive rapid acting insulin market?
What is the breakup of the market based on the product?
Which is the most attractive product in the rapid acting insulin market?
What is the breakup of the market based on the indication?
Which is the most attractive indication in the rapid acting insulin market?
What is the breakup of the market based on the distribution channel?
Which is the most attractive distribution channel in the rapid acting insulin market?
What is the competitive structure of the global rapid acting insulin market?
Who are the key players/companies in the global rapid acting insulin market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Rapid Acting Insulin Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product

6.1 Lispro Insulin
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Aspart Insulin
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Glulisine Insulin
- 6.3.1 Market Trends
- 6.3.2 Market Forecast

7 Market Breakup by Indication

7.1 Type 1 Diabetes
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Type 2 Diabetes
- 7.2.1 Market Trends
- 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

8.1 Hospital Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Drug Stores and Retail Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Online Stores
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 Adocia
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
  - 14.3.1.3 Financials
- 14.3.2 Biocon Limited
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
  - 14.3.2.3 Financials
  - 14.3.2.4 SWOT Analysis
- 14.3.3 Eli Lilly and Company
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
  - 14.3.3.3 Financials
  - 14.3.3.4 SWOT Analysis
- 14.3.4 Gan & Lee Pharmaceuticals Co. Ltd.
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
  - 14.3.4.3 Financials
- 14.3.5 Geropharm
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
- 14.3.6 MannKind Corporation
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
  - 14.3.6.3 Financials
  - 14.3.6.4 SWOT Analysis
- 14.3.7 Merck & Co. Inc.
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
  - 14.3.7.3 Financials
  - 14.3.7.4 SWOT Analysis
- 14.3.8 Novo Nordisk A/S
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
  - 14.3.8.3 Financials
  - 14.3.8.4 SWOT Analysis
- 14.3.9 Sanofi S.A.
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
  - 14.3.9.3 Financials
  - 14.3.9.4 SWOT Analysis
- 14.3.10 Wockhardt Ltd.
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio
  - 14.3.10.3 Financials

簡介目錄圖表

List of Figures

Figure 1: Global: Rapid Acting Insulin Market: Major Drivers and Challenges
Figure 2: Global: Rapid Acting Insulin Market: Sales Value (in Billion USD), 2020-2025
Figure 3: Global: Rapid Acting Insulin Market Forecast: Sales Value (in Billion USD), 2026-2034
Figure 4: Global: Rapid Acting Insulin Market: Breakup by Product (in %), 2025
Figure 5: Global: Rapid Acting Insulin Market: Breakup by Indication (in %), 2025
Figure 6: Global: Rapid Acting Insulin Market: Breakup by Distribution Channel (in %), 2025
Figure 7: Global: Rapid Acting Insulin Market: Breakup by Region (in %), 2025
Figure 8: Global: Rapid Acting Insulin (Lispro Insulin) Market: Sales Value (in Million USD), 2020 & 2025
Figure 9: Global: Rapid Acting Insulin (Lispro Insulin) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 10: Global: Rapid Acting Insulin (Aspart Insulin) Market: Sales Value (in Million USD), 2020 & 2025
Figure 11: Global: Rapid Acting Insulin (Aspart Insulin) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 12: Global: Rapid Acting Insulin (Glulisine Insulin) Market: Sales Value (in Million USD), 2020 & 2025
Figure 13: Global: Rapid Acting Insulin (Glulisine Insulin) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 14: Global: Rapid Acting Insulin (Type 1 Diabetes) Market: Sales Value (in Million USD), 2020 & 2025
Figure 15: Global: Rapid Acting Insulin (Type 1 Diabetes) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 16: Global: Rapid Acting Insulin (Type 2 Diabetes) Market: Sales Value (in Million USD), 2020 & 2025
Figure 17: Global: Rapid Acting Insulin (Type 2 Diabetes) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 18: Global: Rapid Acting Insulin (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
Figure 19: Global: Rapid Acting Insulin (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 20: Global: Rapid Acting Insulin (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
Figure 21: Global: Rapid Acting Insulin (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 22: Global: Rapid Acting Insulin (Online Stores) Market: Sales Value (in Million USD), 2020 & 2025
Figure 23: Global: Rapid Acting Insulin (Online Stores) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 24: North America: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 25: North America: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 26: United States: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 27: United States: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 28: Canada: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 29: Canada: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 30: Asia-Pacific: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 31: Asia-Pacific: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 32: China: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 33: China: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 34: Japan: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 35: Japan: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 36: India: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 37: India: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 38: South Korea: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 39: South Korea: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 40: Australia: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 41: Australia: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 42: Indonesia: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 43: Indonesia: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 44: Others: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 45: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 46: Europe: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 47: Europe: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 48: Germany: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 49: Germany: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 50: France: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 51: France: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 52: United Kingdom: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 53: United Kingdom: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 54: Italy: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 55: Italy: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 56: Spain: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 57: Spain: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 58: Russia: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 59: Russia: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 60: Others: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 61: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 62: Latin America: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 63: Latin America: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 64: Brazil: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 65: Brazil: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 66: Mexico: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 67: Mexico: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 68: Others: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 69: Others: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 70: Middle East and Africa: Rapid Acting Insulin Market: Sales Value (in Million USD), 2020 & 2025
Figure 71: Middle East and Africa: Rapid Acting Insulin Market: Breakup by Country (in %), 2025
Figure 72: Middle East and Africa: Rapid Acting Insulin Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 73: Global: Rapid Acting Insulin Industry: SWOT Analysis
Figure 74: Global: Rapid Acting Insulin Industry: Value Chain Analysis
Figure 75: Global: Rapid Acting Insulin Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Rapid Acting Insulin Market: Key Industry Highlights, 2025 and 2034
Table 2: Global: Rapid Acting Insulin Market Forecast: Breakup by Product (in Million USD), 2026-2034
Table 3: Global: Rapid Acting Insulin Market Forecast: Breakup by Indication (in Million USD), 2026-2034
Table 4: Global: Rapid Acting Insulin Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
Table 5: Global: Rapid Acting Insulin Market Forecast: Breakup by Region (in Million USD), 2026-2034
Table 6: Global: Rapid Acting Insulin Market: Competitive Structure
Table 7: Global: Rapid Acting Insulin Market: Key Players

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

Aspart胰島素市場：按劑型、適應症、強度、年齡層、最終用戶、通路和地區分類

速效型胰島素的全球市場，市場規模和佔有率的分析 - 成長趨勢與預測(2025年～2033年)

速效型胰島素的全球市場的預測:各產品，各適應症，各流通管道，各國，企業的分析

FAQ

速效胰島素市場報告：按產品、適應症、分銷管道和地區分類（2026-2034 年）

Rapid Acting Insulin Market Report by Product, Indication, Distribution Channel, and Region 2026-2034

速效胰島素市場的趨勢與促進因素：

目錄

第1章：序言

第2章：調查方法

第3章執行摘要

第4章：引言

第5章：全球速效胰島素市場

第6章 市場區隔：依產品分類

第7章 市場區隔：依適應症分類

第8章 市場區隔：依分銷通路分類

第9章 市場區隔：依地區分類

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局